Regulatory

Issue and repurchase of series C shares for share saving program

2021-04-09
Download

Pursuant to the authorization granted by the annual general meeting on 6 May 2020, the board of directors of Ascelia Pharma AB (”Ascelia Pharma”) has resolved to issue and immediately thereafter repurchase 397,641 series C shares. The shares are issued and repurchased in accordance with the share saving program LTI 2020, which was adopted by the annual general meeting on 6 May 2020.

Pursuant to the authorization granted by the annual general meeting on 6 May 2020, the board of directors of Ascelia Pharma has resolved on a directed issue of 397,641 series C shares to Svenska Handelsbanken AB. The subscription price per share amounts to SEK 1, which corresponds to the quota value of the shares. Furthermore, the board of directors has resolved to immediately repurchase all 397,641 series C shares from Svenska Handelsbanken AB at a price corresponding to the subscription price.

The purpose of the issue and the repurchase of series C shares is to, when the series C shares have been converted to ordinary shares, ensure delivery of matching shares and performance shares to employees within Ascelia Pharma who are participating in the share saving program LTI 2020, which was adopted by the annual general meeting on 6 May 2020, and, in terms of liquidity, to hedge payments of future social security contributions related to LTI 2020. Allotment of matching shares and performance shares in LTI 2020 shall take place within 30 days from the publication of the financial report for the period June – September 2023.

Since previously, Ascelia Pharma holds 510,545 own series C shares. The series C shares carry one-tenth of a vote per share and do not entitle to dividends.

2021-05-05

Bulletin from the Annual General Meeting in Ascelia Pharma AB on 5 May 2021

Today, on 5 May 2021, the annual general meeting was held in Ascelia Pharma AB. In light of the ongoing Covid-19 pandemic and in order to reduce the risk of infection spreading, the annual general meeting was held only by advance voting (postal vote) in accordance with temporary legislation. A summary of the adopted resolutions follows below. All resolutions were adopted with the required majority of votes.
2021-04-30

Number of shares and votes in Ascelia Pharma AB

2021-04-15

Ascelia Pharma AB publishes prospectus regarding admission to trading of newly issued shares on Nasdaq Stockholm

The board of directors of Ascelia Pharma AB (”Ascelia Pharma” or the “Company”) has, as a result of the directed issue of 5,000,000 shares to a number of Swedish and international institutional investors, that was published on 17 March 2021 and approved by the extraordinary general meeting on 13 April 2021, prepared a prospectus for admission to trading of the new shares on Nasdaq Stockholm. The prospectus does not constitute an offering ...